Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zansecimab
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Zansecimab is a humanized IgG4 monoclonal antibody that selectively targets angiopoietin 2 (Ang2), a key regulator of angiogenesis. By binding to Ang2, zansecimab inhibits its interaction with the Tie2 receptor, thereby blocking phospho-Tie2 induction and suppressing new blood vessel formation. This mechanism was designed to provide anti-tumor effects in solid tumors and has also been investigated for reducing the risk of acute respiratory distress syndrome (ARDS) in patients hospitalized with COVID-19 pneumonia. Zansecimab was developed by Eli Lilly and Company and has undergone clinical evaluation both as monotherapy and in combination with other agents such as ramucirumab[1][2][4][5].
- Other names
- zansecimabLY3127804LY-3127804LY 3127804
02
Targets
ANGPT2 (Angiopoietin-2)
Beyond the preview
Go deeper on zansecimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zansecimab.